Summary of Key Points Core Viewpoint - On February 11, a total of 7 companies had their restricted shares unlocked, with a combined unlock volume of 730 million shares, amounting to a market value of 12.451 billion yuan based on the latest closing prices [1] Group 1: Unlock Volume and Market Value - The companies with the highest unlock volumes were Hailianxun, Qingsong Jianhua, and Mailande, with unlock shares of 426 million, 226 million, and 63.173 million respectively [1] - In terms of unlock market value, Hailianxun, Mailande, and Qingsong Jianhua led with values of 7.696 billion yuan, 2.818 billion yuan, and 1.03 billion yuan respectively [1] Group 2: Unlock Ratio - The companies with the highest unlock ratios relative to their total share capital were Mailande, Hailianxun, and Qingsong Jianhua, with ratios of 63.17%, 28.07%, and 14.08% respectively [1]

Summary of Key Points Core Viewpoint - On February 11, a total of 7 companies had their restricted shares unlocked, with a total unlocking volume of 730 million shares, amounting to a market value of 12.451 billion yuan based on the latest closing prices [1] Group 1: Unlocking Volume - The companies with the highest unlocking volumes were Hailianxun, Qingsong Jianhua, and Mailande, with unlocking shares of 426 million, 226 million, and 6.317 million respectively [1] Group 2: Unlocking Market Value - In terms of unlocking market value, Hailianxun, Mailande, and Qingsong Jianhua led with market values of 7.696 billion yuan, 2.818 billion yuan, and 1.03 billion yuan respectively [1] Group 3: Proportion of Total Share Capital - The companies with the highest proportion of unlocked shares relative to total share capital were Mailande, Hailianxun, and Qingsong Jianhua, with unlocking ratios of 63.17%, 28.07%, and 14.08% respectively [1]

Core Viewpoint - On February 10, a total of 7 listed companies will have their restricted shares unlocked, with a total market value of approximately 5.102 billion yuan [1] Group 1: Company Specifics - Qingsong Jianhua (Stock Code: 600425) will unlock 226 million shares from the issuance of A-shares to original shareholders [1] - Wuchan Jinlun (Stock Code: 002722) will unlock 31.07 million shares from the issuance of A-shares to legal persons [1] - Igor (Stock Code: 002922) will unlock 872,400 shares from equity incentive restrictions [1] - Laisentongling (Stock Code: 603900) will unlock 1.155 million shares from equity incentive restrictions [1] - Xidiwei (Stock Code: 688173) will unlock 1.7208 million shares [1] - Mailande (Stock Code: 688273) will unlock 63.1732 million shares [1] - Yutaiwei (Stock Code: 688515) will unlock 30.1806 million shares [1]

Economic Data - The People's Bank of China will release January CPI and PPI on February 11 [1] - The National Bureau of Statistics will publish the monthly report on January commodity residential sales price index on February 13 [1] - Financial data including January social financing and new RMB loans will also be released next week [1] - In the US, December retail sales month-on-month will be announced on February 10, followed by January unemployment rate and non-farm employment data on February 11 [1] Earnings Reports - The US earnings season continues with several notable companies reporting next week, including BP, Barclays, Marriott, Coca-Cola, and AstraZeneca on February 10 [2] - Other companies such as NetEase, Youdao, and Total will report on February 11, while TripAdvisor and Hyatt will report on February 12 [2] - In Hong Kong, SMIC will report earnings on February 10, followed by Budweiser APAC and NetEase Cloud Music on February 11 [2] New Stock Issuance - One new stock, Tongbao Optoelectronics, will be available for subscription on February 9, with Ai De Technology listing on the Beijing Stock Exchange on February 10 [2] - Several new stocks will list in Hong Kong, including Lanke Technology on February 9 and Aixin Yuanzhi on February 10 [2] Stock Unlocking - A total of 33 restricted stocks will be unlocked next week, with a total market value exceeding 36 billion yuan, led by Hunan YN with 24.096 billion yuan [3][10] Central Bank Operations - The central bank will have 4.055 billion yuan of reverse repos maturing next week, with specific amounts maturing each day [3][10] Government Bonds - The Ministry of Finance will issue the first phase of RMB government bonds in Hong Kong on February 11, with a scale of 14 billion yuan [13]

Group 1: Economic Data Release - The National Bureau of Statistics will release January CPI and PPI data on February 11, with CPI expected to grow by 0.4% year-on-year, influenced by rising pork prices and falling fresh vegetable prices [2] - For PPI, a year-on-year decrease of 1.5% is anticipated, with the factory price index rising by 1.7 percentage points to 50.6% and the main raw material purchase price index increasing by 3 percentage points to 56.1% [2] Group 2: Financial Data Release - Financial data for January, including new loans, M1, M2, and social financing, is expected to be released next week, with new RMB loans projected at 5 trillion yuan, a year-on-year decrease of 130 billion yuan, and a growth rate of 6.2% [3] - Social financing is estimated to increase by 6.9 trillion yuan, down approximately 98 billion yuan year-on-year, with a growth rate of 8.1% [3] - M2 growth is expected to remain steady at 8.5%, while M1 growth is projected to decline to 2.2%, down 1.6 percentage points from the previous month [3] Group 3: Stock Market Developments - The Hang Seng Index Company will announce the results of the fourth quarter index review for 2025 on February 13, 2026, with changes to the constituent stocks effective from March 9, 2026 [4] - A total of 33 restricted stocks will be unlocked next week, with a total market value exceeding 36 billion yuan, peaking on February 9 with 12 companies unlocking a combined value of 30.741 billion yuan [6] - The top three companies by unlock market value are Hunan YN (24.096 billion yuan), Gansu Energy Chemical (4.008 billion yuan), and Mcland (2.744 billion yuan) [6] Group 4: New Stock Opportunities - One new stock, Tongbao Optoelectronics, will be available for subscription on February 9, with an issue price of 16.17 yuan and a total issuance of 1.879 million shares [8][9]

Summary of Key Points Core Viewpoint - A total of 31 companies will have their restricted shares unlocked from February 9 to February 13, with a total of 2.446 billion shares being released, amounting to a market value of 36.293 billion yuan based on the closing price on February 6 [1]. Group 1: Unlocking Details - February 9 is identified as the peak day for share unlocks, with 12 companies releasing shares worth a total of 30.741 billion yuan, which constitutes 84.71% of the total unlocking scale for the week [1]. - The top three companies by market value of unlocked shares are Hunan YN (24.096 billion yuan), Gansu Energy Chemical (4.008 billion yuan), and Meilan De (2.744 billion yuan) [1]. Group 2: Unlocking Volume - The companies with the highest number of unlocked shares are Gansu Energy Chemical (1.623 billion shares), Hunan YN (374 million shares), and Qingsong Jianhua (226 million shares) [1]. Group 3: Types of Restricted Shares - The types of restricted shares being unlocked include 9 from original shareholders of the initial public offering (IPO), 8 from general equity incentives, 5 from directed placements, 5 from restricted equity incentives, 3 from strategic placements of the IPO, 2 from institutional placements of the IPO, and 1 from other types [1].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The medical device bidding market is expected to maintain high prosperity in 2025, driven by policy and demand resonance, with a projected market size of CNY 193.76 billion, representing a year-on-year growth of 24% [3][11] - The upward trend for medical device companies is clear for 2026, with multiple policies expected to support the continuous development of medical innovation [4][29] - The report emphasizes the importance of high-end product localization and innovation in driving growth for leading domestic companies [33][41] Summary by Sections Bidding Review - The medical device bidding market in 2025 is projected to reach CNY 193.76 billion, with a year-on-year increase of 24%, second only to the peak in 2022 [3][11] - Monthly bidding trends show sustained high levels, with procurement amounts from July to December ranging from CNY 134 billion to CNY 285 billion [3][11] - Key segments such as medical imaging equipment and radiation therapy devices are expected to see significant growth, with year-on-year increases of 35.37% and 36.34% respectively [3][16] 2026 Outlook - The report anticipates a clear upward turning point for medical device companies in 2026, supported by policies aimed at promoting medical innovation and equipment updates [4][29] - The implementation of large-scale equipment updates and consumer replacement policies is expected to further stimulate market demand [4][29] - The report highlights the potential for domestic companies to benefit from high-end product upgrades and the commercialization of brain-computer interface technologies [4][50] Investment Recommendations - The report suggests focusing on leading domestic companies that are enhancing their high-end and intelligent medical device offerings, such as Mindray, United Imaging, and KaiLi Medical [4][33] - It also recommends monitoring companies involved in brain-computer interfaces and domestic robotics, which are expected to see significant growth in the coming years [4][50]

Group 1 - Nanjing Lanxi Brain-Machine Technology Co., Ltd. has been established with a registered capital of 20 million RMB, fully owned by Nanjing Mailande Medical Technology Co., Ltd. [1] - The legal representative of the new company is Yang Ruijia, and it is located in Jiangsu Province, Nanjing City, Xixia District, at the Jiangsu Life Science Park [1] - The business scope includes the production and operation of second and third-class medical devices, internet information services related to medical devices, and various technology services such as development, consulting, and transfer [1] Group 2 - The company is classified under the national standard industry of scientific research and technical services, specifically in professional technical services and industrial design [1] - The company is registered as a limited liability company with a business duration until February 2, 2026, with no fixed term thereafter [1] - The registration authority is the Nanjing Xixia District Administrative Service Management Office [1]

Core Viewpoint - The announcement details the upcoming listing and circulation of restricted shares for Nanjing Mailland Medical Technology Co., Ltd., which will take place on February 11, 2026, involving a total of 63,173,210 shares, representing 63.1732% of the company's total share capital [2][4][24]. Group 1: Listing Details - The type of stock being listed is restricted shares from the initial public offering (IPO), with a total of 63,173,210 shares set for circulation [2][24]. - The shares will be available for trading starting on February 11, 2026 [4][25]. Group 2: Share Capital Changes - Following the IPO, the company's total share capital was established at 100 million shares, with 77,642,626 shares subject to restrictions and 22,357,374 shares unrestricted [4]. - The total share capital increased to 100.62 million shares after the first grant of restricted stock in May 2023, but was later reduced back to 100 million shares due to the termination of the stock incentive plan in April 2024 [5][6]. Group 3: Shareholder Commitments - Shareholders holding restricted shares have made commitments regarding the lock-up period, including not transferring shares for 36 months post-IPO and adhering to specific conditions for any future share sales [8][10][14]. - If the stock price falls below the IPO price for a specified period, the lock-up period will automatically extend by at least six months [8][10][14]. Group 4: Compliance and Verification - The sponsor institution, Nanjing Securities Co., Ltd., has verified that the shareholders have complied with their commitments regarding the restricted shares, confirming that the listing and circulation of these shares meet legal and regulatory requirements [22][23].

证券代码：688273 证券简称：麦澜德 公告编号：2026-002 南京麦澜德医疗科技股份有限公司 关于首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 63,173,210股。 六次会议，审议通过了《关于向激励对象首次授予限制性股票的议案》。公司于 2023 年 5 月 9 日完成了 2023 年限制性股票激励计划第一类限制性股票授予登记工 作，公司总股本由 10,000 万股增加至 10,062 万股。具体内容详见公司于 2023 年 5 月 11 日在上海证券交易所网站（www.sse.com.cn）披露的《2023 年限制性股票激 励计划第一类限制性股票授予结果公告》（公告编号：2023-027）。 本次股票上市流通总数为63,173,210股。 本次股票上市流通日期为2026 年 2 月 11 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会出具的《关于同意南京麦澜德医疗科技股份有 限 ...